Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01721577Phase 1Terminated

Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas

Role: collaborator

NCT01725555Phase 1Completed

A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

Role: lead

NCT01561456Phase 2Completed

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Role: lead

NCT01466647Phase 1Completed

A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

Role: lead

NCT01062620Phase 1Completed

A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

Role: lead

All 5 trials loaded